Mesenchymal Stem Cells: Market Research Report

December 2018 | 167 pages | ID: MF74EB89B9FEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 47 companies including many key and niche players such as -

• Aastrom Biosciences, Inc.
• Cell Applications, Inc.
• Celprogen, Inc.
• Cyagen US Inc.
• Genlantis, Inc.
• Lonza Group
• Mesoblast Limited

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2. MARKET OVERVIEW

Mesenchymal Stem Cells Market on a Rapid Growth Path
Current and Future Analysis
The Present and Future of MSC Therapies
Select MSC-based Therapeutics
Mesenchymal Stem Cell Research

Table 1. Mesenchymal Stem Cells-based (MSCs) Clinical Trials by Category (2018) (includes corresponding Graph/Chart)

Completed Phase III Studies with MSCs
MSCs are Being Explored for Several New Treatment Possibilities
Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
Software Companies Endeavour to Cash in on the Boom

3. MARKET DRIVERS, TRENDS & ISSUES

Development of Regenerative Medicine Accelerates Demand for MSCs

Table 2. Global Regenerative Medicines Market by Category (2016): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering (includes corresponding Graph/Chart)

Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
Global Aging Population Statistics – Opportunity Indicators

Table 3. Elderly Population (60+ Years) as a Percentage of Total Population (2017 & 2050) (includes corresponding Graph/Chart)

Table 4. Global Aging Population (2017 & 2050): Population of 60+ Individuals in ‘000s and as a Percentage of Total Population (includes corresponding Graph/Chart)

Table 5. Life Expectancy for Select Countries in Number of Years: 2018 (includes corresponding Graph/Chart)

Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
Key Disease Statistics – Opportunity Indicators

Table 6. Worldwide Incidence of Cancer (2012, 2018 & 2040): Number of New Cases Diagnosed (includes corresponding Graph/Chart)

Table 7. World Cancer Incidence by Geographic Region and Gender (2018): Number of New Cancer Cases Reported (in Thousands) for Asia-Pacific, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)

Table 8. World Cancer Incidence by Cancer Type (2018): Number of New Cancer Cases Reported (in Thousands) for Breast, Cervix uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach and Others (includes corresponding Graph/Chart)

Table 9. Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)

Table 10. Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)

Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market

Table 11. Global Orthopedic Market by Segment (2018): Percentage Breakdown of Value Sales for Arthroscopy / Soft Tissue, Extremities, Hips, Knees, Orthobiologics, Spine, Trauma and Others (includes corresponding Graph/Chart)

Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
Adult Stem Cells and Embryonic Stem Cells - A Comparison
MSCs Versus Embryonic or Induced Pluripotent Stem Cells
MSC Therapies – Immune to Ethical Issues Applicable to Embryonic Stem Cells
MSCs – A Potential Vehicle for 'Targeted Drug Delivery'
Stem Cell Based Bone Grafts: Promising Growth Ahead
Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
Major Challenges Confronting Mesenchymal Stem Cell Market
Allogeneic MSCs – Offering Promise in Immunosuppressive and Tissue Repair Therapy
Administration Route Determines the Effectiveness of MSCs

4. REVIEW OF SELECT MAJOR STEM CELL VARIANTS

Adult Stem Cells
A Low Risk Investment
Adult Stem Cells Garner More Investments for Research
Low Versatility – A Major Limiting Factor for Adult Stem Cells
Hematopoietic Stem Cells – Enjoying Enduring Success
Restraining Factors
Induced Pluripotent Stem Cells – An Alternative to ESCs
A Peek into the Discovery of iPS
Drug Development – A Major Application for iPS
Use of iPS for Regenerative Medicine
Establishing iPS Cell Banks
Intractable and Congenital Disease Treatments
Embryonic Stem Cells to Transfigure Medicine
Ethical Issues and Technical Hurdles Bog Down hESC Research
Lack of Safety and Efficacy Data – A Key Concern

5. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION

Mesenchymal Stem Cells in Orthopedics
MSC based Models for Orthopedic Repair
Delivery of MSCs to Regions Requiring Therapy
MSCs in the Treatment of Osteoarthritis
MSCs in the Treatment of Rheumatoid Arthritis
MSCs in Cancer Treatment
MSCs in Hepatology
MSCs in Neurology
MSCs in Cardiology
MSCs in Radiotherapy
MSCs in the Treatment of Diabetes
MSCs in the Treatment of Autoimmune Diseases
MSCs in Treatment of Premature Ovarian Failure
MSCs for Gene Therapy
MSC Therapy in the Treatment of Lung Diseases
MSCs for Treating Liver Disease
MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US (2016)
MSCs in Colon Repair
MSCs in Kidney Repair

6. PRODUCT OVERVIEW

Mesenchymal Stem Cells (MSCs) – An Introduction
History
What Are Allogeneic Mesenchymal Stem Cells?
Some Major Sources of Mesenchymal Stem Cells
Bone Marrow
Wharton's Jelly and Umbilical Cord Blood
Adipose Tissue
Trophoblastic Tissues
Amniotic Fluid
Developing Tooth Bud of Mandibular Third Molar
Mechanism of Mesenchymal Stem Cell Therapy
Important Features of Mesenchymal Stem Cells
Morphology
Identification/Detection
Differentiation Capacity
Immuno-modulatory Effects
Culturing
Clinical Use
Production of Clinical-Grade MSCs
Drawbacks of MSCs

7. COMPETITIVE LANDSCAPE

7.1 Focus on Select Players
Cell Applications, Inc. (USA)
Celprogen, Inc. (USA)
Cyagen US Inc. (USA)
Genlantis, Inc. (USA)
Lonza Group (Switzerland)
Mesoblast Limited (Australia)
MilliporeSigma (USA)
Neuromics (USA)
Orthofix International N. V. (Italy)
PromoCell GmbH (Germany)
R&D Systems, Inc. (USA)
ScienCell Research Laboratories (USA)
Stemcell Technologies Inc. (Canada)
Stemedica Cell Technologies, Inc. (USA)
Thermo Fischer Scientific, Inc. (USA)
Vitro Biopharma (USA)
7.2 Product Launches
RoosterBio Launches CliniControl (CC) Product Portfolio
Provia Labs Launches Library of Stem Cell Material Available for Researchers
JCR Pharmaceuticals Develops TEMCELL HS
PuRec Announces Plans to Produce MSCs/RECs
7.3 Recent Industry Activity
Mesoblast Partners with Tasly for MPC Products
SanBio Acquires Patent Portfolio Regarding Cell Medicines Derived from MSC
Otsuka to Acquire New Shares Issued by TWO CELLS
Stemedica Receives FDA Approval for Phase Iia Clinical Study for Traumatic Brain Injury
Stemedica Enrolls into Phase I/IIa Clinical Study for Ischemic Stroke

8. GLOBAL MARKET PERSPECTIVE

Table 12. World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 13. World Historic Review for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 Through 2014 (includes corresponding Graph/Chart)

Table 14. World 14-Year Perspective for Mesenchymal Stem Cells by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2018 & 2022 (includes corresponding Graph/Chart)

9. REGIONAL MARKET PERSPECTIVE

9.1 The United States
A. Market Analysis
Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies

Table 15. The US Elderly Population by Age Group in Million (2016-2050) (includes corresponding Graph/Chart)

Increasing Incidence of Chronic Diseases Drives Focus onto MSCs

Table 16. CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)

Table 17. New Cancer Cases in Males in US by Body Site (2018) (includes corresponding Graph/Chart)

Table 18. New Cancer Cases in Females in US by Body Site (2018) (includes corresponding Graph/Chart)

Arthritis

Table 19. % of Population Diagnosed with Arthritis by Age Group (includes corresponding Graph/Chart)

Prochymal Obtains Fast Track Designation from FDA
MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US
Rising Governmental Investments in Stem Cell Therapies – A Growth Booster
FDA Issues Warning Against Illegal Stem Cell Therapies
US Regulates Stem Cells as Drugs
Federal Law on Stem Cells in the US
NIH at the Forefront of Research Funding
NIH Guidelines on Stem Cell Research Funding
Bans and Restrictions on Stem Cell Research
American Type Culture Collection Inc (ATCC) – A Major Non-Profit Organization
B. Market Analytics

Table 20. The US Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 21. The US Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

9.2 Canada
A. Market Analysis
Current and Future Analysis
Prochymal – Canada’s First MSC-based Therapy
B. Market Analytics

Table 22. Canadian Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 23. Canadian Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

9.3 Japan
A. Market Analysis
Current and Future Analysis
Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Mesenchymal Stem Cells

Table 24. Japanese Population by Age Group (2015 & 2040): Percentage Share Breakdown of Population for 0-14, 15-64 and 65 & Above Age Groups (includes corresponding Graph/Chart)

Table 25. Cancer Related Incidence and Deaths by Site in Japan: 2018 (includes corresponding Graph/Chart)

New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market
B. Market Analytics

Table 26. Japanese Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 27. Japanese Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

9.4 Europe
A. Market Analysis
Current and Future Analysis
Ageing Population to Drive Demand for MSC based Therapies

Table 28. European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above (includes corresponding Graph/Chart)

Table 29. European Country-wise Statistics of 65+ Population as % of Total Population: 2018 & 2030 (includes corresponding Graph/Chart)

Cancer in Europe: Key Statistics

Table 30. Cancer Related Incidence and Deaths by Site in Europe: 2018 (includes corresponding Graph/Chart)

Legislations on Stem Cell Research and Therapy in the EU
Unproven Stem Cell Therapies Receive Government Backing in the EU?
Scientists and Government Tussle over Safety of Stamina Foundation’s MSC Therapy in Italy
Stem Cell Clinics Shut Down in Germany due to Malpractices
B. Market Analytics

Table 31. European Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 32. European Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

9.5 Asia-Pacific
A. Market Analysis
Current and Future Analysis
Overview of Select Countries
Australia
Stem Cell Tourism – A Popular Trend in Australia
South Korea
South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
South Korea Upbeat on Stem Cell Therapy Market Potential
India
An Outline of the Stem Cell Research Structure in India
A Regulatory Picture of the Indian Stem Cell Research and Therapy
Adult Stem Cells – A Highly Money-Spinning Market
Indians 'Bank' on Dental Stem Cells
New Zealand
Stem Cell Research Scenario in New Zealand
B. Market Analytics

Table 33. Asia-Pacific Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 34. Asia-Pacific Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

9.6 Rest of World
A. Market Analysis
Current and Future Analysis
Stem Cell Research in Full Swing in Israel
B. Market Analytics

Table 35. Rest of World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 36. Rest of World Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

10. COMPANY PROFILES

Total Companies Profiled:
The United States (25)
Canada (1)
Japan (2)
Europe (6)
  Germany (2)
  The United Kingdom (1)
  Rest of Europe (3)
Asia-Pacific (Excluding Japan) (9)
Latin America (1)
Middle East (3)